Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966793 | 0.78 | ADRA1A (0.41) | ADRA1A | |
| SCHEMBL6968544 | 0.78 | TRPA1 (0.43) | ADRA1A | |
| SCHEMBL6967627 | 0.78 | DRD4 (0.43) | SLC6A4 | |
| SCHEMBL6968121 | 0.77 | IDO1 (0.35) | SLC6A4ALOX5APFEN1ADRA1A | |
| SCHEMBL6954794 | 0.76 | CHRNB2 (0.51) | SLC6A2SLC6A4ADRA1A | |
| SCHEMBL6956374 | 0.75 | P2RX7 (0.36) | P2RX7SLC6A2SLC6A4ALOX5APFEN1 | |
| SCHEMBL6966951 | 0.75 | REN (0.37) | SLC6A2SLC6A4ALOX5APFEN1ADRA1A | |
| SCHEMBL6964292 | 0.75 | ADRA1A (0.41) | ADRA1A | |
| SCHEMBL6961834 | 0.74 | ADRA1A (0.40) | SLC6A2SLC6A4ADRA1A | |
| SCHEMBL6967051 | 0.73 | P2RX7 (0.38) | P2RX7ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | P2RX7 213/4885SLC6A2 1098/4885SLC6A4 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.